IMG_0162

Following on from the workshop held during the Helsinki convention, LUPUS EUROPE organised a Patient panel, bringing together 10 people living with lupus, from 7 countries, to share their experience about “treatment”, with a view to help improving the quality of life of people living with lupus. The Panel was conducted through a series of interactive presentations, team discussions and working groups, and resulted in the drafting of 3 letters addressed respectively to: People living with lupus, Patient Organisations, and the medical community; suggesting how they can each help in their respective areas.

The key points highlighted during the two day event were:

“Treatment” is broad; it is both medicine based and non-drug based, and can be categorised in three ways – core, medical, and well being. Treatment can be defined as any product or activity that aims at improving quality of life for the person with lupus.

Access includes ease of contact with Health Care Practitioners and support services such as orthotics as well as availability of medicines.  The individual’s personal adherence can be reinforced or weakened by the relationship with the Health Care Practitioner.

Patients will take new medicine provided they understand the reasons why and the side effects; management of patient expectations in terms of medication (speed of noticeable effects) and relating to support staff are equally important for correct treatment compliance.

We noted a dual-faceted infusion experience, as viewed by the person with lupus; it can either be viewed as an experience which emphasises their own incapacity or one which they view as contributing to their long-term quality of life.

Patient Organisations have a critical role to play, creating a community, sharing reliable information, providing hope, raising awareness and advocating for lupus.

Please read the report available here (members only area). If you have forgotten your login or password to access the members’ section, send an email to secretariat@lupus-europe.org 

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

📣 Upcoming ERN RECONNET Webinar on Lupus Nephritis!

➡️ “What is the added value of triple therapy in lupus nephritis” ⬅️

🗓 11 March 2026
⏰ 4:00 p.m. CET (i.e., Paris time).

🎙 Speaker: Dr Antonis Fanouriakis
🎙 Moderators: Prof. Dr Matthias Schneider & Zoe Karakikla-Mitsakou, General Secretary of Lupus Europe.

Lupus nephritis remains one of the most serious complications of systemic lupus erythematosus, and treatment strategies continue to evolve as new evidence emerges.

🔎 This webinar will explore:
•⁠ ⁠The scientific rationale for triple therapy.
•⁠ ⁠Current clinical evidence.
•⁠ ⁠What this may mean for outcomes in lupus nephritis.

Whether you are a healthcare professional, researcher, or patient, this session is not to be missed!

Register now! us06web.zoom.us/webinar/register/WN_41Lc9osLQ6m7nOuJGGWnHw#/registration
... See MoreSee Less

📣 Upcoming ERN RE

🚨 New publication alert: EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement- 2025 update.

‼️ According to Lupus Europe's 2024 Swiss knife survey:

1️⃣ Kidney involvement remains one of the most worrying and impactful lupus manifestations for many people in Europe.
2️⃣ Kidney problems are among the manifestations causing the greatest long-term concern.
3️⃣ Only a small minority of patients report long-term stability without flares.
4️⃣ Patients want clearer goals, better communication, and care that looks beyond lab values alone.

That is why the 2025 update of the EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement is such an important step forward.

✅ These updated recommendations reinforce several key messages that matter to patients:
- Early and regular monitoring of kidney involvement.
- Timely kidney biopsy when needed.
- Clear treatment targets to preserve kidney function.
- A strong focus on combination therapies when appropriate.
- Long-term kidney protection, not only short-term control.

🌟 We are especially proud that our Chair, Jeanette Andersen, was part of the international task force that developed these recommendations, ensuring that the patient perspective was present at the table.

You can read the EULAR Recommendations here: ard.eular.org/article/S0003-4967(25)04412-7/fulltext

And the Swiss Knife Survey here: www.sciencedirect.com/science/article/pii/S1568997225000989
... See MoreSee Less

🚨 New publication

😃 Thank you to all who attended our latest Youth Group webinar!

🌟 So many interesting questions were asked and addressed! Showing how important safe spaces arefor talking openly about lupus without judgment.

Did you miss it? Watch it here! 👇

Alcohol & Drugs - Lupus
... See MoreSee Less

😃 Thank you to al
LUPUS EUROPE Uniting people with Lupus throughout Europe
Send